An objective test for adult ADHD.
About 4% of women have ADHD, frequently undiagnosed until adulthood. DatChem-Neuro records the neurochemical pathways behind it, moving beyond the questionnaire to objective measurement.
A condition often missed until adulthood.
About 4% of women have ADHD, and it is frequently undiagnosed until adulthood.
In women it tends to present as inattentive, restless, overwhelmed, disorganised and emotion-sensitive rather than hyperactive, so it is easily overlooked. Many experience exhaustion, anxiety and depression along the way. Yet the current test is a questionnaire. DatChem makes it objective.
- Often undiagnosed. Frequently missed until adulthood, particularly in women.
- A quieter presentation. Inattentive, restless, overwhelmed and emotion-sensitive rather than hyperactive.
- Beyond the questionnaire. Objective measurement in place of self-report alone.
Recording the chemistry behind ADHD.
DatChem-Neuro records five dysfunctional neurochemical pathways in women with ADHD, then measures them again as treatment unfolds.
Five pathways recorded
Records five dysfunctional neurochemical pathways in women with ADHD, directly from a standard MRI.
Three of five respond
Only three of the five pathways respond to lisdexamfetamine, so the test can show whether, and how, a treatment is working.
Her own control
Each person is their own control, therapy response is monitored objectively over time, scan after scan.
DatChem's technologies are undergoing regulatory evaluation (TGA, FDA and EMA) and are not yet approved for routine clinical use in all markets.
One family of brain chemistry.
ADHD sits within DatChem's neuro family alongside PTSD, built on the same patented spectroscopy, with a clinical trial planned.
Alongside PTSD
ADHD joins PTSD within the DatChem-Neuro family, one approach to the chemistry of the brain.
Patented detection
The underlying spectroscopy and the ADHD spectral detection are both patented.
Trial planned
An ADHD clinical trial is planned, beginning in Australia with global intent.
From scan to report, on existing scanners.
DatChem-Neuro adds a short sequence to a standard MRI, no new hardware, with results returned to the physician in minutes.
Patient scan
A short sequence on a standard MRI captures the raw spectral data, no contrast, no biopsy.
Data capture
Raw data is transmitted securely from the scanner to the DatChem cloud.
Data processing
The chemical signature is extracted and compared against our exclusive databases.
Physician report
A report reaches the physician in minutes, mapping the pathways involved.
Bring DatChem-ADHD to your centre.
For clinical, research or partnership enquiries about DatChem-ADHD, we'd be glad to hear from you.